Substantial progress in the treatment of atherosclerotic complications – in particular in secondary prevention – has led to a significant reduction of recurrent cardiovascular events. This has been through the use of pharmacological strategies including lipid-lowering drugs such as statins, beta-blockers, angiotensin-converting ensyme inhibitors and angiotensin receptor blockers, along with the introduction of early percutaneous coronary intervention in acute coronary syndrome with consecutive application of dual antiplatelet therapy.
Atherosclerosis
Atherosclerosis
About
Media
Watch time: 3m 25s
Watch time: 7m 44s
Watch time: 9m 40s
Articles
Guest Editorial: Commentary on the Findings of the GLAGOV Randomized Clinical Trial
Citation:
US Cardiology Review 2017;11(1):18–9
- Views:
449
- Downloads:
0
Dual Anti-platelet Therapy after Coronary Stenting: Rationale for Personalized Duration of Therapy
Citation:
US Cardiology Review 2017;11(1):31–6
- Views:
3887
- Downloads:
0
Guest Editorial: A Brave New World for Non-vitamin K Antagonist Oral Anticoagulants: Have We seen the Last of Warfarin?
Citation:
US Cardiology Review 2017; 11(1):37–8
- Views:
366
- Downloads:
0
Evaluation and Diagnosis of Pulmonary Arterial Hypertension
Citation:
US Cardiology 2005;2(1):1–6
- Views:
83
- Downloads:
1